Company to present preclinical data for AB-201, an anti-HER2-specific CAR-NK cell therapy candidate developed with Artiva’s AlloNKTM Platform Data highlight scaled production and anti-tumor activity in support of clinical development for the treatment of HER2+ solid tumors SAN DIEGO, October 21, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing…
